Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06668064 · ClinicalTrials.gov registry record · Phase 3
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
A Phase 3 study of Wet Age-related Macular Degeneration and wAMD, sponsored by EyePoint Pharmaceuticals.
- Active
- Registry status
- Phase 3
- Development phase
- 400
- Enrollment target
- 20
- Study locations
NCT06668064 is a Phase 3 study of Wet Age-related Macular Degeneration and wAMD that is active but no longer recruiting, run by EyePoint Pharmaceuticals. The registered enrollment target is 400 participants, roughly in line with the 374-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target. The trial reports 20 study locations across 6 states.
The verdict
NCT06668064, a Phase 3 study of Wet Age-related Macular Degeneration and wAMD, is active but no longer recruiting, sponsored by EyePoint Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 400 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
Conditions Studied
Interventions
- DRUG EYP-1901
- DRUG Aflibercept (2.0 mg)
Study Locations (20)
California
- California Retina Consultants - Bakersfield
- Retina Vitreous Associates Medical Group - Beverly Hills
- Macula and Retina Institute - Glendale
- Retina Consultants San Diego - Poway
- Retina Consultants of Southern California - Redlands
- Retinal Consultants Medical Group - Sacramento
- West Coast Retina Medical Group - San Francisco
- Bay Area Retina Associates - Walnut Creek
- American Institute of Research - Whittier
Colorado
- RSC Research, PLLC - Denver
- Eye Center of Northern Colorado, PC - Fort Collins
- Advanced Vision Institute - Longmont
Connecticut
- Connecticut Eye Consultants, P.C. - Danbury
- SightSera Clinical Research LLC - Greenwich
- Retina Group of New England, PC - Waterford
Florida
- Advanced Research, LLC - Deerfield Beach
- Florida Retina Consultants - Lakeland
- Florida Retina Institute - Orlando
Arizona
- Retinal Research Institute, LLC - Phoenix
Arkansas
- Retina Partners of Northwest Arkansas - Springdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2024-10-22 |
| Est. Completion | 2027-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06668064
The ClinicalTrials.gov registry entry for NCT06668064 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 400 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 374-participant average among 8 other Wet Age-related Macular Degeneration trials with a reported enrollment target. The listed sponsor is EyePoint Pharmaceuticals, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Wet Age-related Macular Degeneration appearing as the primary indexed condition, and to 2 interventions - of which EYP-1901 is the first listed.
NCT06668064 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Colorado, Connecticut.
Frequently Asked Questions
What is clinical trial NCT06668064 about?
NCT06668064 is a clinical study titled "A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56". This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept.
What is the current status of trial NCT06668064?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 400 participants. The study started on 2024-10-22. Estimated completion is 2027-08.
What conditions does trial NCT06668064 study?
This clinical trial studies the following conditions: Wet Age-related Macular Degeneration, wAMD.
What interventions are being tested in trial NCT06668064?
The interventions under investigation include: EYP-1901 (DRUG), Aflibercept (2.0 mg) (DRUG).
Who is sponsoring clinical trial NCT06668064?
This trial is sponsored by EyePoint Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06668064 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Wet Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
ACTIVE NOT RECRUITING · Phase 3
-
A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD)
COMPLETED · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
-
Long-term Study of ADVM-022 in Neovascular (Wet) AMD [OPTIC-EXT]
ACTIVE NOT RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.